Replies to post #237898 on Biotech Values

[Whalatane]

Thx Dew. Looks like most benefit ( less itching ) is for dialysis patients however I don’t think that market is as large s the Co expects

No position

Kiwi

[DewDiligence]

CARA—(-49%)—flops again in pruritis/AD—discontinues program:

https://finance.yahoo.com/news/cara-therapeutics-announces-outcome-dose-120000127.html

Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with atopic dermatitis